Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06595160 · ClinicalTrials.gov registry record
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
A clinical trial of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8, sponsored by Emory University.
- Recruiting
- Registry status
- 87
- Enrollment target
- 1
- Study location
NCT06595160 is a study of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8 that is actively recruiting participants, run by Emory University. The registered enrollment target is 87 participants, above the 79-participant average among 5 other Resectable Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06595160, a study of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2027-08-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06595160
The ClinicalTrials.gov registry entry for NCT06595160 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 79-participant average among 5 other Resectable Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (10% higher). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Resectable Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06595160 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06595160 about?
NCT06595160 is a clinical study titled "Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy". This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
What is the current status of trial NCT06595160?
This trial is currently recruiting. The enrollment target is 87 participants. The study started on 2024-08-05. Estimated completion is 2027-08-07.
What conditions does trial NCT06595160 study?
This clinical trial studies the following conditions: Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Borderline Resectable Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06595160?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06595160?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06595160 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Phase II Study of Neoadjuvant FOLFIRINOX
COMPLETED · Phase 2
Explore more on PlainTrial
Resectable Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Stage I Pancreatic Cancer AJCC v8
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.